NCT05700617 · University of Chicago
Cardiac Power Output in Cardiogenic Shock Patients
What this study is about
The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.
View original scientific description
The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.
Interventions
DRUG
1:1 Randomization to receive milrinone
Randomized to receive either inotropic agent: milrinone or no agent
Primary outcome measures
Changes in invasive hemodynamics using a pulmonary artery (PA) catheter measuring mmHg
Time frame: Baseline and 6,12,24,36,72 Hours post-inotrope challenge.
Changes invasive hemodynamics representing myocardial reserve will be measured in 5 patients using a pulmonary artery (PA) catheter: Pulmonary capillary wedge pressure (PCWP mmHg); Right Atrial pressure (RA mmHg); Pulmonary Atrial pressures (PA mmHg);
Changes in invasive hemodynamics using a pulmonary artery (PA) catheter measuring L/min/m2
Time frame: Baseline and 6,12,24,36,72 Hours post-inotrope challenge.
Changes invasive hemodynamics representing myocardial reserve will be measured in 5 patients using a pulmonary artery (PA) catheter: Cardiac output by Fick (CO L/min/m2); Cardiac index by Fick (CI L/min/m2).
Advanced heart failure therapy
Time frame: 2 years
Duration of time without need for definitive advanced heart failure therapy (LVAD, OHT) or death.
Inotropes
Time frame: 2 years
Duration of time on inotropes during hospitalization
Death
Time frame: 2 years
Cardiovascular death and/or all-cause mortality
Cardiac output measurement using a pulmonary artery (PA) catheter measuring mmHg at 2 years
Time frame: 2 years
Efficacy of increasing cardiac output with milrinone compared to dobutamine using changes invasive hemodynamics in 5 patients using a pulmonary artery (PA) catheter: Pulmonary capillary wedge pressure (PCWP mmHg), Right Atrial pressure (RA mmHg), Pulmonary Atrial pressures (PA mmHg),
Cardiac output measurement using a pulmonary artery (PA) catheter measuring CO L/min/m2 at 2 years
Time frame: 2 years
Efficacy of increasing cardiac output with milrinone compared to dobutamine using changes invasive hemodynamics in 5 patients using a pulmonary artery (PA) catheter: Cardiac output by Fick (CO L/min/m2), Cardiac index by Fick (CI L/min/m2.)
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Referred for RHC for:
- Evaluation for advanced heart failure therapies, including LVAD, OHT, temporary or long-term inotrope therapy, or counter-pulsation (temporary or long-term with NuPulse device OR
- Accurate assessment of invasive hemodynamics due to worsening clinical status, OR
- Assessment of myocardial recovery for consideration of LVAD or counter-pulsation (temporary IABP or long-term with NuPulse device) decommissioning or removal OR
- Assessment of cardiac function and valvular abnormalities prior to planned valvular surgery for MR or AI
- Estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73 m2
- Age ≥ 18 years-old
- Intent for admission based on RHC data
Exclusion criteria
- eGFR \< 30 ml/min/1.73 m2
- Severe, non-revascularized coronary artery disease
- Concurrent acute coronary syndrome
- Age \< 18 years-old
- History of significant ventricular arrhythmia without an ICD
Where
- Chicago, Illinois
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Aug 6, 2026 · Source of record for eligibility and locations